comparemela.com

Latest Breaking News On - Pieris pharmaceuticals inc view - Page 2 : comparemela.com

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

District of columbiaUnited statesJoe patneaudeGewinn nurPieris pharmaceuticalsAmerican thoracic societyPieris pharmaceuticals incCompany quarterly reports on formPieris pharmaceuticals inc viewInternational conferenceSecurities exchangeExchange commissionChief development officerSecurities actSecurities exchange actAnnual report

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023

BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesJoe patneaudePieris pharmaceuticals incPieris pharmaceuticals inc viewPieris pharmaceuticalsToll freeRelations contactInc view

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDTContinued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional therapeutic

United statesStephens yoderExchange commissionSecurities exchangeCompany quarterly reports on formPieris pharmaceuticals inc viewPieris pharmaceuticals incPieris pharmaceuticalsBoston pharmaceuticalsAstrazeneca collaborationOncology pipelineServier collaborationYear end financial updateToll freeSecurities actSecurities exchange act

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesStephens yoderSociety for immunotherapy of cancerPieris pharmaceuticalsCompany quarterly reports on formCompany annual report on formExchange commissionPieris pharmaceuticals inc viewSecurities exchangePieris pharmaceuticals incAnnual meetingLooking statementsSecurities actSecurities exchange actAnnual reportQuarterly reports

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

United statesMaria kelmanPieris pharmaceuticals inc viewPieris pharmaceuticalsPieris pharmaceuticals incJefferies london healthcare conferenceRelations contactInc view

vimarsana © 2020. All Rights Reserved.